Skip to main navigation
Logo

Press Releases

Press Releases

Date Title View
September 27, 2023 Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer
August 29, 2023 Caribou Biosciences to Participate in Upcoming Investor Conferences
August 8, 2023 Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
July 13, 2023 Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
July 13, 2023 Caribou Biosciences Announces Proposed Public Offering of Common Stock
July 13, 2023 Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
July 6, 2023 Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
May 31, 2023 Caribou Biosciences to Participate in Upcoming Investor Conferences
May 9, 2023 Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 8, 2023 Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

 

 


Toolkit

Print Page

Email Alerts

RSS Feeds

Investor Contact

Main Menu

  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Leadership
    • Board of Directors
    • Committee Composition
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Results
  • IR Resources
    • FAQs
    • Email Alerts
    • Contact IR
  • More
    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • CAR-NK cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical trials
    • Careers
      • Job Opportunities
      • Values
      • DE&I
      • Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    Main Menu

    • About
      • Leadership
      • Board of Directors
      • Scientific Advisory Board
      • Partnering
    • Technology
      • chRDNA technology
      • CAR-T cell therapy platform
      • CAR-NK cell therapy platform
      • Scientific publications
    • Pipeline
      • T cell pipeline
      • NK cell pipeline
      • Clinical trials
    • Careers
      • Job Opportunities
      • Values
      • DE&I
      • Benefits
    • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Analyst Coverage
      • Corporate Governance
        • Documents & Charters
        • Leadership
        • Board of Directors
        • Committee Composition
      • Financials & Filings
        • SEC Filings
        • Annual Reports
        • Quarterly Results
      • IR Resources
        • FAQs
        • Email Alerts
        • Contact IR
    • Contact

    logo

    Caribou Biosciences, Inc.
    2929 7th Street, Suite 105
    Berkeley, CA 94710
    Tel: 510-982-6030
    info@cariboubio.com

    ©  Caribou Biosciences, Inc. All rights reserved.

    02. Footer Copyright Links

    • Privacy Policy
    • Terms of Use

    03. Footer Social Links

    • Twitter
    • linkedin